menu
    • menu
    [{"orgOrder":0,"company":"SciMar","sponsor":"Source Nutraceutical, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atropine","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"SciMar","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciMar \/ Source Nutraceutical, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"SciMar \/ Source Nutraceutical, Inc."},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"ASPR","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Atropine","moa":"||mAChR","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Meridian Medical Technologies \/ ASPR","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ ASPR"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"US Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Atropine","moa":"||mAChR","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kindeva Drug Delivery \/ US Department Of Health And Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Kindeva Drug Delivery \/ US Department Of Health And Human Services"},{"orgOrder":0,"company":"Teligent, Inc","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Atropine","moa":"||mAChR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Teligent, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Teligent, Inc \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Teligent, Inc \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atropine","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UT Southwestern Medical Center \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Chiesi Group"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atropine","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Arctic Vision","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"||mAChR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Arctic Vision","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Arctic Vision"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"||mAChR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Bausch Health"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atropine","moa":"||mAChR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atropine","moa":"||mAChR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Atropine","moa":"||mAChR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Spray","sponsorNew":"Bausch & Lomb Incorporated \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Eyenovia"},{"orgOrder":0,"company":"Ohio State University","sponsor":"University of Houston | State University of New York | Pennsylvania College of Optometry | Southern California College of Optometry at Marshall B. Ketchum University | University of California, Berkeley | Stanford University | Case Western Reserve Univers","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atropine","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ohio State University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ohio State University \/ University of Houston | State University of New York | Pennsylvania College of Optometry | Southern California College of Optometry at Marshall B. Ketchum University | University of California, Berkeley | Stanford University | Case Western Reserve Univers","highestDevelopmentStatusID":"6","companyTruncated":"Ohio State University \/ University of Houston | State University of New York | Pennsylvania College of Optometry | Southern California College of Optometry at Marshall B. Ketchum University | University of California, Berkeley | Stanford University | Case Western Reserve Univers"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atropine","moa":"||mAChR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"China Medical University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atropine","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kubota Pharmaceutical \/ China Medical University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Kubota Pharmaceutical \/ China Medical University Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals for Atropine Methyl Nitrate

    Menu

    Atropine Methyl Nitrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kindeva Drug Delivery

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Kindeva Drug Delivery

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Pralidoxime Chloride

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : US Department Of Health And Human Services

                            Deal Size : $129.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Kindeva Secures $129M SNS Contract for Nerve Agent Antidote

                            Details : The funding aims to advance the the manufacturing of DuoDote (atropine and pralidoxime chloride). It is indicated for the treatment of poisoning by organophosphorus nerve agents.

                            Product Name : Duodote

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 16, 2025

                            Lead Product(s) : Atropine,Pralidoxime Chloride

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : US Department Of Health And Human Services

                            Deal Size : $129.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eyenovia

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eyenovia Provides Update On Phase 3 CHAPERONE Study

                            Details : A drug-device combination of low-dose atropine in the Company’s Optejet dispensing platform is being investigated as a potential treatment for pediatric progressive myopia.

                            Product Name : MicroPine

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 15, 2024

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bausch & Lomb Incorporated

                            Canada arrow
                            EPSC
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Eyenovia

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Eyenovia Re-Acquires Development Rights To Micropine in U.S. and Canada

                            Details : Eyenovia re-acquired rights to MicroPine in the U.S. and Canada, expanding its phase III pipeline, being evaluated as a potential treatment for pediatric progressive myopia.

                            Product Name : MicroPine

                            Product Type : Other Small Molecule

                            Upfront Cash : $5.0 million

                            January 16, 2024

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Eyenovia

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Meridian Medical Technologies

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Meridian Medical Technologies

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Pralidoxime Chloride

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : ASPR

                            Deal Size : $9.9 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Meridian Medical Technologies, Kindeva Drug Delivery’s Global Health Security Division, Awarded Contract to ...

                            Details : Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent anti...

                            Product Name : DuoDote

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 14, 2023

                            Lead Product(s) : Atropine,Pralidoxime Chloride

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : ASPR

                            Deal Size : $9.9 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kubota Pharmaceutical

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Kubota Pharmaceutical

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : China Medical University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Electronic Spectacles Versus Low Dose Atropine in Young Myopes

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 13, 2023

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : China Medical University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ohio State University

                            Country arrow
                            EPSC
                            Not Confirmed

                            Ohio State University

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : University of Houston | State University of New York | Pennsylvania College of Optometry | Southern California College of Optometry at Marshall B. Ketchum University | University of California, Berkeley | Stanford University | Case Western Reserve Univers

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Delaying the Onset of Nearsightedness Until Treatment Study

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 08, 2023

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : University of Houston | State University of New York | Pennsylvania College of Optometry | Southern California College of Optometry at Marshall B. Ketchum University | University of California, Berkeley | Stanford University | Case Western Reserve Univers

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                            Country arrow
                            EPSC
                            Not Confirmed

                            Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MAD Trial: Myopia Atropine Dose

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 28, 2022

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Teligent, Inc

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Teligent, Inc

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : $45.8 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Hikma Expands Into Canada with Acquisition of Teligent Sterile Injectable Assets

                            Details : The acquisition marks Hikma’s expansion into Canada and a portfolio of 25 sterile injectable products including the marketed product Atropine-G, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approv...

                            Product Name : Atropine-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 17, 2022

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : $45.8 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            UT Southwestern Medical Center

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            UT Southwestern Medical Center

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Fentanyl

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase IV

                            Sponsor : Chiesi Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Premedication for Less Invasive Surfactant Administration Study (PRELISA)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 04, 2021

                            Lead Product(s) : Atropine,Fentanyl

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Chiesi Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Eyenovia

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Bausch Health

                            Deal Size : $45.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression ...

                            Details : Bausch Health has acquired an exclusive license in the U.S and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of nearsightedness,...

                            Product Name : MicroPine

                            Product Type : Other Small Molecule

                            Upfront Cash : $10.0 million

                            December 10, 2020

                            Lead Product(s) : Atropine,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Bausch Health

                            Deal Size : $45.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth